Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for protein-protein interfaces.
Fig. 1. The sreening workflow of Receptor.AI
It includes extensive molecular simulations of the target alone and in complex with its most relevant partner proteins, followed by ensemble virtual screening that accounts for conformational mobility in free and bound forms. The tentative binding pockets are considered on the protein-protein interface itself and in remote allosteric locations in order to cover the whole spectrum of possible mechanisms of action.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P32970
UPID:
CD70_HUMAN
Alternative names:
CD27 ligand; Tumor necrosis factor ligand superfamily member 7
Alternative UPACC:
P32970; B4DPR8; Q53XX4; Q96J57
Background:
The CD70 antigen, also known as CD27 ligand or Tumor necrosis factor ligand superfamily member 7, plays a pivotal role in the immune system. It is a cytokine that binds to CD27, crucial for T cell immunity, especially during antiviral responses. This interaction promotes T-cell proliferation and the development of cytolytic T-cells.
Therapeutic significance:
CD70's involvement in Lymphoproliferative syndrome 3, an immunologic disorder leading to increased susceptibility to Epstein-Barr virus and B-cell malignancies, highlights its therapeutic potential. Targeting the CD70-CD27 pathway could offer new strategies for treating this syndrome and related B-cell disorders.